UCB Wins Patent Order Blocking Copies of Briviact Epilepsy Drug

UCB SA won a decision blocking copies of Briviact until 2026, as a federal judge upheld the validity of a patent three generic-drug makers had conceded their proposed versions of the epilepsy treatment infringe.

• Judge Colm F. Connolly, in an opinion issued Wednesday in the US District Court for the District of Delaware, rejected arguments by Apotex Inc., Annora Pharma Private Ltd., and MSN Laboratories Private Ltd. that the patent should be voided for covering an obvious invention.
• US Patent No. 6,911,461 covers the compound brivaracetam, Briviact’s active ingredient.
• UCB sued seven generic-drug makers in July 2020; Apotex, ...